Clinical benefit of neoadjuvant chemoradiotherapy for the avoidance of pneumonectomy; assessment in 12 consecutive centrally located non-small cell lung cancers
Authors:
- 21 April 2017
- journal article
- research article
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 65 (7) , 392-399
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2010
- Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response☆European Journal of Cardio-Thoracic Surgery, 2008
- Multimodality treatment of unresectable stage III non–small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapyThe Journal of Thoracic and Cardiovascular Surgery, 2006
- Pulmonary Resection After High-Dose and Low-Dose Chest IrradiationThe Annals of Thoracic Surgery, 2005
- Low Morbidity and Mortality for Bronchoplastic Procedures With and Without Induction TherapyThe Annals of Thoracic Surgery, 2005
- Pulmonary Resection After Curative Intent Radiotherapy (>59 Gy) and Concurrent Chemotherapy in Non–Small-Cell Lung CancerThe Annals of Thoracic Surgery, 2004
- Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrencesThe Annals of Thoracic Surgery, 2004
- Parenchymal sparing operations for bronchogenic carcinomaSurgical Clinics of North America, 2002
- Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.Journal of Clinical Oncology, 1998
- Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.Journal of Clinical Oncology, 1995